Ovid Therapeutics Inc. OVID · Stock Open Ovid Therapeutics Inc. in new tab
Ovid Therapeutics Inc. Analysis (OVID)
Is Ovid Therapeutics Inc. a good investment? Ovid Therapeutics Inc. (OVID) is currently trading at 2.71 USD. Market analysts have a consensus price target of 5.92 USD. This suggests a potential upside from current levels.
Earnings Schedule: Ovid Therapeutics Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -0.39.
Investor FAQ
Does Ovid Therapeutics Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Ovid Therapeutics Inc.?
Ovid Therapeutics Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -0.21.
Company Profile
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Community Discussion